2022年12月22日

據知情人士透露，紅杉中國(Sequoia China)在投資大師沈南鵬(Neil Shen)的帶領下，已經籌集了約90億美元用於科技和醫療保健投資，克服了困擾風險投資行業的融資挑戰。該公司的運營基本獨立於總部位於矽穀的紅杉資本(Sequoia Capital)。知情人士稱，該公司從來自美國、歐洲、中東和東南亞的養老金、捐贈基金和家族理財室籌集了資金。由於此事是私人事務，這些人要求不具名。知情人士補充稱，盡管人們擔心監管加強和經濟放緩，但紅杉中國長期看好中國的增長，並計劃投資於有助於推動製藥和醫療保健等行業發展的尖端技術。在中國對民營企業的打壓和疫情導致的經濟放緩期間，這家投資公司脫穎而出，因為中國的風險投資同行都在努力籌集資金。隨著投資者重新評估他們在中國的風險敞口，紅杉資本(Sequoia)和IDG資本(IDG Capital)等較為成熟的基金正在吸引大量資金，而規模較小和較新的基金則難以找到支持者。知情人士說，這筆資金將分配給四個基金:紅杉資本中國擴張基金I、紅杉資本中國種子基金III、紅杉資本中國創業基金IX和紅杉資本中國增長基金VII。他們補充說，投資者超額認購了約50%，但該公司決定堅持最初的目標範圍。紅杉中國在一份電子郵件聲明中拒絕置評。《信息報》此前報道了該公司的融資計劃。紅杉資本(Sequoia Capital)及其北京子公司花了十多年時間，在中國眾多創業公司中投入了100多億美元，為字節跳動(ByteDance Ltd.)和京東(JD.com Inc.)等公司提供了資金支持，同時也成為了打算在中國發大財的風投公司中的強大品牌。 The prospects for investments in China are mired in uncertainty, as regulatory actions on both sides of the Pacific squeeze the nation’s technology industry and create unpredictability for its financial backers. Putting aside a stock rally that began on the mainland last quarter, China is still weathering a decline in venture capital investments, despite once being touted as a primary rival to Silicon Valley. The value of deals in the country fell roughly 40% from a year ago to $34 billion in the first five months of 2022, according to data from research firm Preqin. Meanwhile, venture capital and private equity funds raised $6.2 billion, a drop of more than 90% compared to the first five months of last year. Chinese tech stocks have taken a beating in the past year, driving down valuations in the industry and spurring investors to allocate money into the country’s top investment outlets instead of less established ones. The healthcare industry, which hasn’t yet been a focus of Beijing’s recent crackdowns, represents about a third of Sequoia China’s portfolio companies, the people said. Technology and consumer startups also account for one third each, they added. Share this article: